Michael Jackson, PhD, MPH

“Group Health gives us nearly unlimited potential to address vaccine effectiveness and safety questions of national and international importance.”

Michael L. Jackson, PhD, MPH

Group Health Research Institute Associate Investigator

Biography

Michael L. Jackson’s research focuses on understanding how infectious diseases spread, and on designing and evaluating interventions such as vaccination programs. Dr. Jackson is the Group Health Research Institute (GHRI) principal investigator for the United States Influenza Vaccine Effectiveness Network. This Network aims to provide ongoing evaluations of the U.S. influenza vaccination program. Dr. Jackson uses data from this Network to study influenza vaccine effectiveness, to estimate the burden of disease caused by influenza, and to advance the methodology of vaccine effectiveness studies. He also uses mathematical models to predict the impact of vaccination programs on the spread of infectious diseases such as Haemophilus influenza type b (Hib) and Neisseria meningitidis.

Dr. Jackson is a co-investigator on the Vaccine Safety Datalink (VSD) Project. The VSD, a collaboration among nine U.S. managed care organizations and the Centers for Disease Control and  Prevention (CDC), is the world’s premier system for post-licensure studies of vaccine safety. As a VSD co-investigator, Dr. Jackson leads studies of the  safety of childhood immunizations and develops methods for using managed care  data for vaccine safety studies.

While studying for his PhD at the University of  Washington, Dr. Jackson was a graduate research associate with GHRI from 2002 to 2007, and then a postdoctoral fellow at GHRI from 2007 to 2008. He then spent two years as an Epidemic Intelligence Service (EIS) officer with the CDC in Atlanta. As an EIS officer, Dr. Jackson helped lead investigations of whooping cough outbreaks and of the 2009 influenza pandemic. He also designed and oversaw an enhanced surveillance system for invasive Hib disease in the U.S. during the 2008–2009 shortage of Hib vaccines. He returned to GHRI as an assistant investigator in 2010.

Research interests and experience

 

 

 

Recent publications

Jackson ML, Walker R, Lee S, Larson E, Dublin S. Predicting 2-year risk of developing pneumonia in older adults without dementia. J Am Geriatr Soc. 2016 Jul;64(7):1439-47. doi: 10.1111/jgs.14228. PubMed

Hutcheon JA, Fell DB, Jackson ML, Kramer MS, Ortiz JR, Savitz DA, Platt RW. Detectable risks in studies of the fetal benefits of maternal influenza vaccination. Am J Epidemiol. 2016 Jun 30. pii: kww048. [Epub ahead of print]. PubMed

Texier G, Farouh M, Pellegrin L, Jackson ML, Meynard JB, Deparis X, Chaudet H. Outbreak definition by change point analysis: a tool for public health decision? BMC Med Inform Decis Mak. 2016 Mar 12;16(1):33. doi: 10.1186/s12911-016-0271-x. PubMed

Jackson ML, Bellamy A, Wolff M, Hill H, Jackson LA. Low-dose aspirin use does not diminish the immune response to monovalent H1N1 influenza vaccine in older adults. Epidemiol Infect. 2016 Mar;144(4):768-71. doi: 10.1017/S0950268815002058. Epub 2015 Sep 2. PubMed